# A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)

> **NCT07487311** · — · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 80 (estimated)

## Conditions studied

- Inflamatory Bowel Disease

## Interventions

- **DRUG:** guselkumab (GUS), JAK inhibitors (such as upadacitinib/tofacitinib)

## Key facts

- **NCT ID:** NCT07487311
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-07
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07487311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07487311, "A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07487311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*